Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)

Phase Distribution

Ph phase_1
3
100%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

terminated3100%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_1

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

NCT05501912
terminatedphase_1

A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

NCT05892653
terminatedphase_1

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

NCT04190628

Clinical Trials (3)

Showing 3 of 3 trials
NCT05501912Phase 1

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Terminated
NCT05892653Phase 1

A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

Terminated
NCT04190628Phase 1

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3